Category: Europe

September 20, 2021 Off

Santhera nets CHF 45 Million in funding

By Dino Mustafić

Santhera Pharmaceuticals has announced a cahs boost with an oversubscribed equity financing of CHF 20 million, a placement of private convertible bonds of CHF 15 million and upsizing of an existing financing arrangement of up to CHF 10 million.

September 13, 2021 Off

USFDA accepts Novartis’ tislelizumab for people with esophageal cancer

By Dino Mustafić

Novartis got an acceptance by the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for anti-PD-1 immune checkpoint inhibitor tislelizumab for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had received prior systemic therapy.

July 19, 2021 Off

Lonza and CN Bio in new distribution agreement

By Dino Mustafić

Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM Organ-On-a-Chip (OOC) range of Single- and Multi-Organ Microphysiological Systems (MPS)

July 17, 2021 Off

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

By BusinessWire

The study, which included people living with HIV and healthcare teams and overlapped with the COVID-19 pandemic, demonstrated that Cabenuva (a co-pack with two injectable medicines including ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine) can be successfully implemented across a range of healthcare settings in the US.

July 16, 2021 Off

EMA validates Hutchmed’s Surufatinib

By Dino Mustafić

The European Medicines Agency (EMA) has validated and accepted Chinese HUTCHMED Limited’s marketing authorization application (MAA) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (NETs).